Suntinorexton

Suntinorexton
Clinical data
Drug class	Orexin OX2 receptor agonist
Identifiers
	IUPAC name N-[(2S,3S)-2-[[2-fluoro-3-(3-fluorophenyl)phenyl]methyl]-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide;
CAS Number	2274802-89-8 ;
PubChem CID	137460941;
UNII	FF2NQ35DA4;
Chemical and physical data
Formula	C23H28F2N2O4S
Molar mass	466.54 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCS(=O)(=O)N[C@H]1CCN([C@H]1CC2=C(C(=CC=C2)C3=CC(=CC=C3)F)F)C(=O)C(C)(C)O;
	InChI InChI=1S/C23H28F2N2O4S/c1-4-32(30,31)26-19-11-12-27(22(28)23(2,3)29)20(19)14-16-8-6-10-18(21(16)25)15-7-5-9-17(24)13-15/h5-10,13,19-20,26,29H,4,11-12,14H2,1-3H3/t19-,20-/m0/s1; Key:MQDUVMBBJZLFHF-PMACEKPBSA-N;

Suntinorexton (INNTooltip International Nonproprietary Name) is an experimental orexin receptor agonist.^[1] It acts as a selective agonist of the orexin OX₂ receptor and was described in 2019 in a patent by Takeda Pharmaceutical Company.^[2] It is being evaluated for the treatment of narcolepsy.^[3]

Quick Facts Clinical data, Drug class ...

Close

See also